Affiliation between Neu5Gc carbohydrate and serum antibodies in opposition to it supplies the molecular hyperlink to most cancers: French NutriNet-Santé research
Background: Excessive consumption of pink and processed meat is usually related to elevated most cancers danger, notably colorectal most cancers. Antibodies in opposition to the pink meat-derived carbohydrate N-glycolylneuraminic acid (Neu5Gc) exacerbate most cancers in “human-like” mice. Human anti-Neu5Gc IgG and pink meat are each independently proposed to extend most cancers danger, but how weight-reduction plan impacts these antibodies is essentially unknown.
Strategies: We used world world knowledge to exhibit that colorectal most cancers incidence and mortality are related to elevated nationwide meat consumption. In a well-defined massive cohort, we used glycomics to measure day by day Neu5Gc consumption from pink meat and dairy, and investigated serum in addition to affinity-purified anti-Neu5Gc antibodies.
Primarily based on 24-h dietary data, day by day Neu5Gc consumption was calculated for 19,621 topics aged ≥ 18 years of the NutriNet-Santé research. Serum and affinity-purified anti-Neu5Gc antibodies have been evaluated by ELISA and glycan microarrays in consultant 120 people, every with at the very least eighteen 24-h dietary data (aged 45-60, Q1-This fall; aged > 60, Q1 and This fall; 10 males/girls per quartile).
Outcomes: We discovered that high-Neu5Gc weight-reduction plan, gender, and age have an effect on the specificity, ranges, and repertoires of anti-Neu5Gc IgG immune responses, however not their affinity. Males consumed extra Neu5Gc than girls, principally from pink meat (p = 0.0015), and exhibited greater general serum anti-Neu5Gc IgG ranges by ELISA (3.94 ng/μl versus 2.22 ng/μl, respectively; p = 0.039). Detailed glycan microarray evaluation in opposition to 56 totally different glycans revealed excessive Neu5Gc-specificity with elevated anti-Neu5Gc IgG and altered repertoires, related to greater consumption of Neu5Gc from pink meat and cow dairy.
Affinity purification of serum anti-Neu5Gc antibodies revealed elevated ranges and biased array repertoire patterns, with out a rise in antibody affinity, in people consuming greater Neu5Gc ranges. Moreover, in a high-meat weight-reduction plan, antibody variety patterns on glycan microarrays shifted in the direction of Neu5Gcα3-linked glycans, rising the α3/α6-glycans ratio rating.
Conclusions: We discovered a transparent hyperlink between the degrees and repertoire of serum anti-Neu5Gc IgG and Neu5Gc consumption from pink meat and dairy. These exact rational methodologies allowed to develop a Gcemic index to simplify the evaluation of Neu5Gc in meals that would doubtlessly be tailored for dietary suggestions to cut back most cancers danger.
Molecular Mechanism of HER2 Fast Internalization and Redirected Trafficking Induced by Anti-HER2 BiparatopicAntibody
- Amplification and overexpression of HER2 (human epidermal development issue receptor 2), an ErbB2 receptor tyrosine kinase, have been implicated in human most cancers and metastasis. A bispecific tetravalent anti-HER2 antibody (anti-HER2-Bs), focusing on two non-overlapping epitopes on HER2 in area IV (trastuzumab) and area II (39S), has been reported to induce speedy internalization and environment friendly degradation of HER2 receptors.
- On this research, we investigated the molecular mechanism of this antibody-induced speedy HER2 internalization and intracellular trafficking. Utilizing quantitative fluorescent imaging, we in contrast the internalization kinetics of anti-HER2-Bs and its parental arm antibodies, alone or in mixtures and beneath numerous internalization-promoting circumstances. The outcomes demonstrated that concurrent engagement of each epitopes was crucial for speedy anti-HER2-Bs internalization.
- Mobile uptake of anti-HER2-Bs and parental arm antibodies occurred by way of clathrin-dependent endocytosis; nonetheless, contained in the cells antibodies directed totally different trafficking pathways. Trastuzumab dissociated from HER2 in 2 h, enabling the receptor to recycle, whereas anti-HER2-Bs stayed related to the receptor all through the whole endocytic pathway, selling receptor ubiquitination, trafficking to the lysosomes, and environment friendly degradation.
- In keeping with routing HER2 to degradation, anti-HER2-Bs considerably decreased HER2 shedding and altered its exosomal export. Collectively, these outcomes allow a greater understanding of the mechanism of motion of anti-Her2-Bs and may information the rational design of anti-HER2 therapeutics in addition to different bispecific molecules.
Receptor-binding domain-specific human neutralizing monoclonal antibodies in opposition to SARS-CoV and SARS-CoV-2
The outbreaks of extreme acute respiratory syndrome (SARS) and Coronavirus Illness 2019 (COVID-19) brought on by SARS-CoV and SARS-CoV-2, respectively, have posed extreme threats to world public well being and the economic system. Therapy and prevention of those viral illnesses name for the analysis and growth of human neutralizing monoclonal antibodies (NMAbs).
Scientists have screened neutralizing antibodies utilizing the virus receptor-binding area (RBD) as an antigen, indicating that RBD incorporates a number of conformational neutralizing epitopes, that are the principle structural domains for inducing neutralizing antibodies and T-cell immune responses. This assessment summarizes the construction and performance of RBD and RBD-specific NMAbs in opposition to SARS-CoV and SARS-CoV-2 at the moment beneath growth.
Bacillus Calmette-Guérin-induced perinuclear antineutrophil cytoplasmic antibodies associated vasculitis in bladder cancer
Intravesical instillation of Bacillus Calmette-Guérin (BCG) immunotherapy remains the most effective adjuvant treatment for noninvasive bladder cancer. Systemic BCG-related complications are rare and usually related to infective agent or an immune-mediated reaction. We discussed a case with perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) vasculitis, developing after instillation of BCG for non-invasive bladder cancer. A 68-year-old man presented with nephritic syndrome a few months after BCG instillations which was performed for his non-muscle-invasive bladder cancer adjuvant therapy.
The renal function had declined slowly after the first instillation and urinary sediment reveals the new onset of nephritic proteinuria and hematuria. High titer of p-ANCA was present. His renal biopsy was consistent with acute renal vasculitis. The patient’s creatinine level regressed with immunosuppressive therapy and he was clinically followed up without hemodialysis. Here, we presented a patient that diagnosed as p-ANCA related vasculitis occurred after BCG instillation.
Attenuation of antibody titer of measles and rubella virus among university students of department of healthcare providers during 2015-2018 in Japan
Background: In Japan, measles elimination was confirmed in March 2015. Nevertheless, some outbreaks with cases imported from abroad were reported even after certification. A large rubella outbreak has been occurring since 2017. This study examines measurement of the speed of attenuation of antibody titer for a measles virus comparison with rubella virus.
Method: Student subjects born from April 2, 1996 through April 1, 2000 were selected at Ibaraki Prefectural University of Health Sciences for this study: 177 for measles and 114 for rubella. They had available dates of additional immunization and antibodies in the following period and were judged as requiring additional immunization. We used enzyme immunoassay for IgG antibody testing. We regressed post-antibody titers of measles or rubella on pre-antibody titers and functions of duration between inoculation to post-evaluation. Functions of duration were selected according to the adjusted coefficient of determination.
Results: For measles, only a linear term of duration or log of duration was found to be significant without the quadratic terms. For rubella, we selected a five-order linear model which indicated that titer after vaccination would converge to 19.2.
Discussion: Results demonstrate that measles antibody decreased monotonically. If the pre-antibody titer was 15, vaccination raised titer quickly to 26; then it attenuated by 0.014 per day. Antibody titer is expected to be less than 16, which is the protection level of titer, after 704 days. For rubella, however, when pre-vaccination titer was evaluated at its average, the lower limit was 19.2. Therefore, protection can be maintained for a long time. This difference might reflect some circumstances of outbreaks of the respective diseases.
Conclusion: This report describes the speed of attenuation and the epidemiological situation. The speed of attenuation can be expected to rise. Therefore, additional vaccination every several years might be necessary to maintain a protection level if a disease is almost eliminated.
 Recombinant Human Galectin-1 Protein |
|||
| PROTP09382-1 | BosterBio | 50ug | EUR 380.4 |
|
Description: Lectins, of either plant or animal origin, are carbohydrate binding proteins that interact with glycoprotein and glycolipids on the surface of animal cells. The Galectins are lectins that recognize and interact with β-galactoside moieties. Galectin-1 is an animal lectin that has been shown to interact with CD3, CD4, and CD45. It induces apoptosis of activated T-cells and T-leukemia cell lines and inhibits the protein phosphatase activity of CD45. Recombinant human Galectin-1 is a 14.5 kDa protein containing 134 amino acid residues. |
|||
 Anti-Galectin-3 Monoclonal Antibody |
|||
| M00621-1 | BosterBio | 100ul | EUR 476.4 |
|
Description: Mouse Monoclonal Galectin-3 Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat. |
|||
 Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
 anti-Galectin 1 |
|||
| YF-PA12945 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Galectin 1 |
|||
 HRP-Goat Anti-Mouse Secondary Antibody |
|||
| A12003 | EpiGentek |
|
|
 HRP-Goat Anti-Rabbit Secondary Antibody |
|||
| A12004 | EpiGentek |
|
|
 Goat Anti-Rabbit Secondary Antibody, Biotin Conjugated |
|||
| A12001 | EpiGentek |
|
|
 Goat Anti-Rat Secondary Antibody, Biotin Conjugated |
|||
| A12002 | EpiGentek |
|
|
 Anti-Galectin 1 Antibody |
|||
| A00470-2 | BosterBio | 100ug/vial | EUR 352.8 |
 Anti-Galectin-1 antibody |
|||
| PAab03314 | Lifescience Market | 100 ug | EUR 426 |
 anti- Galectin-1 antibody |
|||
| FNab03314 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin-1 |
|||
anti- Galectin-1 antibody |
|||
| FNab03315 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against Galectin-1 |
|||
Anti-Galectin-1 antibody |
|||
| STJ93201 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-1. |
|||
Anti-Galectin-1 antibody |
|||
| STJ98716 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-1. |
|||
) Anti-Galectin 1 (1A8) |
|||
| YF-MA13984 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Galectin 1 |
|||
) Human Galectin-1 (LGALS1) |
|||
| 1-CSB-EP012882HU | Cusabio |
|
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
|||
Human Galectin-1 (LGALS1) |
|||
| 1-CSB-EP012882HUb1 | Cusabio |
|
|
|
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli |
|||
 Human Genomic DNA |
|||
| X11000 | EpiGentek |
|
|
 Anti-Galectin 1/Lgals1 Antibody |
|||
| A00470 | BosterBio | 100ug/vial | EUR 400.8 |
 Anti-Galectin 1 Biotinylated Antibody |
|||
| A00470-Biotin | BosterBio | 50ug/vial | EUR 352.8 |
) anti-Galectin 1 (1E8-1B2) |
|||
| LF-MA10174 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Galectin 1 |
|||
 Anti-Galectin 1/LGALS1 Antibody |
|||
| PA1422 | BosterBio | 100ug/vial | EUR 400.8 |
Anti-Galectin 1/LGALS1 Antibody |
|||
| PB9240 | BosterBio | 100ug/vial | EUR 400.8 |
 antibody) Anti-galectin-1 (mouse) antibody |
|||
| STJ72519 | St John's Laboratory | 100 µg | EUR 430.8 |
 Human Brain Genomic DNA |
|||
| X11001 | EpiGentek |
|
|
 / Placental Protein 13 (PP13) Monoclonal Antibody) Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody |
|||
| M08143-1 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human. |
|||
 Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
 Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
 LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag |
|||
| PROTO00214-1 | BosterBio | Regular: 10ug | EUR 380.4 |
|
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
|||
 LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag |
|||
| PROTP17931-1 | BosterBio | Regular: 25ug | EUR 380.4 |
|
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_ |
|||
 LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag |
|||
| PROTP47929-1 | BosterBio | Regular: 20ug | EUR 380.4 |
|
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques. |
|||
 AssayMax ELISA Kit) Human Galectin-3 (Gal-3) AssayMax ELISA Kit |
|||
| EG3311-1 | AssayPro | 96 Well Plate | EUR 572.4 |
 AssayMax ELISA Kit) Human Galectin-4 (Gal-4) AssayMax ELISA Kit |
|||
| EG3312-1 | AssayPro | 96 Well Plate | EUR 572.4 |
 anti-Galectin 3 |
|||
| YF-PA24079 | Abfrontier | 50 ul | EUR 400.8 |
|
Description: Mouse polyclonal to Galectin 3 |
|||
 anti-galectin 9 |
|||
| YF-PA24081 | Abfrontier | 50 ul | EUR 400.8 |
|
Description: Mouse polyclonal to galectin 9 |
|||
anti-Galectin 3 |
|||
| YF-PA12946 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to Galectin 3 |
|||
anti-Galectin 3 |
|||
| YF-PA12947 | Abfrontier | 100 ul | EUR 483.6 |
|
Description: Rabbit polyclonal to Galectin 3 |
|||
anti-Galectin 3 |
|||
| YF-PA12948 | Abfrontier | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal to Galectin 3 |
|||
 anti-Galectin 8 |
|||
| YF-PA12951 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to Galectin 8 |
|||
 anti-Galectin 13 |
|||
| YF-PA18585 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to Galectin 13 |
|||
 ELISA kit) Human Galectin-1(LGALS1) ELISA kit |
|||
| 1-CSB-EL012882HU | Cusabio |
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human Galectin-1(LGALS1) in samples from serum, plasma, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
|||
 Recombinant Human Galectin-1 |
|||
| 7-00427 | CHI Scientific | 10µg | Ask for price |
Recombinant Human Galectin-1 |
|||
| 7-00428 | CHI Scientific | 50µg | Ask for price |
Recombinant Human Galectin-1 |
|||
| 7-00429 | CHI Scientific | 1mg | Ask for price |
 Human Galectin 1 Protein |
|||
| 20-abx066725 | Abbexa |
|
|
 Galectin-1, human recombinant |
|||
| 4648-10 | Biovision | each | EUR 170.4 |
Galectin-1, human recombinant |
|||
| 4648-1000 | Biovision | each | EUR 1977.6 |
Galectin-1, human recombinant |
|||
| 4648-50 | Biovision | each | EUR 314.4 |
 Anti-human Galectin-3 antibody |
|||
| STJ15100163 | St John's Laboratory | 250 µg | EUR 403.2 |
|
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation |
|||
) Bovine Galectin-1 (LGALS1) |
|||
| 1-CSB-EP012882BO | Cusabio |
|
|
|
Description: Recombinant Bovine Galectin-1(LGALS1) expressed in E.coli |
|||
 SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag |
|||
| E80025 | EpiGentek |
|
|
 Anti-Galectin-9 Antibody |
|||
| A03415 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat. |
|||
 Anti-Galectin 2 antibody |
|||
| PAab03310 | Lifescience Market | 100 ug | EUR 494.4 |
 Anti-Galectin 4 antibody |
|||
| PAab03311 | Lifescience Market | 100 ug | EUR 426 |
 Anti-Galectin 8 antibody |
|||
| PAab03312 | Lifescience Market | 100 ug | EUR 426 |
 Anti-Galectin 9 antibody |
|||
| PAab03313 | Lifescience Market | 100 ug | EUR 426 |
 Anti-Galectin-3 antibody |
|||
| PAab03316 | Lifescience Market | 100 ug | EUR 426 |
 Anti-Galectin-7 antibody |
|||
| PAab03318 | Lifescience Market | 100 ug | EUR 426 |
) anti-Galectin-3 (6G2) |
|||
| LF-MA20336 | Abfrontier | 100 ug | EUR 424.8 |
|
Description: Mouse monoclonal to Galectin-3 |
|||
 anti- Galectin 2 antibody |
|||
| FNab03310 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against Galectin 2 |
|||
 anti- Galectin 4 antibody |
|||
| FNab03311 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin 4 |
|||
 anti- Galectin 8 antibody |
|||
| FNab03312 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin 8 |
|||
 anti- Galectin 9 antibody |
|||
| FNab03313 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin 9 |
|||
 anti- Galectin-3 antibody |
|||
| FNab03316 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin-3 |
|||
anti- Galectin-3 antibody |
|||
| FNab03317 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against Galectin-3 |
|||
 anti- Galectin-7 antibody |
|||
| FNab03318 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Galectin-7 |
|||
 Anti-Galectin-2 antibody |
|||
| STJ93202 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-2. |
|||
 Anti-Galectin-4 antibody |
|||
| STJ93203 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-4. |
|||
Anti-Galectin-7 antibody |
|||
| STJ93204 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-7. |
|||
 Anti-Galectin-8 antibody |
|||
| STJ93205 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-8. |
|||
 Anti-Galectin-9 antibody |
|||
| STJ93206 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Galectin-9. |
|||
Anti-Galectin-3 antibody |
|||
| STJ96945 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins. |
|||
Anti-Galectin-3 antibody |
|||
| STJ97549 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (6B8). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97550 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (8D7). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97551 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (5D9). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97601 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (2F9). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97604 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (16E6). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97605 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3 (1H4). |
|||
Anti-Galectin-3 antibody |
|||
| STJ97715 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Mouse monoclonal to Galectin-3. |
|||
Anti-Galectin-3 antibody |
|||
| STJ16100369 | St John's Laboratory | 1 mL | EUR 1256.4 |
Anti-Galectin-3 antibody |
|||
| STJ16100782 | St John's Laboratory | 100 µg | EUR 864 |
Anti-Galectin-3 antibody |
|||
| STJ180106 | St John's Laboratory | 0.1 ml | EUR 254.4 |
 Anti-Galectin 3 antibody |
|||
| STJ190057 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24) |
|||
Anti-Galectin 3 antibody |
|||
| STJ73098 | St John's Laboratory | 100 µg | EUR 430.8 |
) Anti-Galectin 8 (3E5) |
|||
| YF-MA13986 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to Galectin 8 |
|||
 Galectin 1 antibody |
|||
| 70R-11939 | Fitzgerald | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal Galectin 1 antibody |
|||
Galectin 1 antibody |
|||
| 70R-49997 | Fitzgerald | 100 ul | EUR 292.8 |
|
Description: Purified Polyclonal Galectin 1 antibody |
|||
